Skip to main content
. Author manuscript; available in PMC: 2018 Mar 20.
Published in final edited form as: Exp Hematol. 2016 Sep 17;45:74–84. doi: 10.1016/j.exphem.2016.09.003

Figure 4.

Figure 4

Inhibition of AKT activity decreases myeloid and erythroid differentiation of human HSPCs. (A) Inhibition of AKT activity delays myeloid differentiation of CD34+ cells. Purified CD34+ cells were cultured in myeloid-promoting medium containing DMSO (0.01%) or AKTi (1 μmol/L). The percentage of myeloid cells (CD11b+) was determined at day 9. (B) Purified CD34+ cells cultured in erythroid-promoting medium containing DMSO (0.01%) or AKTi (1 μmol/L). The percentage of mature erythroid cells (CD71+/GlyA+) was determined at day 5. (C) Inhibition of AKT activity in CD34+ cells deceases the generation of mature erythroid cells (*p < 0.05, n = 3).